China Resources Group: Ropivacaine Long-Acting Injection approved to conduct clinical trials in China.

According to an announcement by the Shi Pharm Group on the Hong Kong Stock Exchange, the long-acting injection of ropivacaine developed by Shi Pharm Group has been approved by the National Medical Products Administration of the People's Republic of China and can be used in clinical trials in China. The approved clinical indication for this study is postoperative pain relief. The approval of the clinical trial for this product is expected to fill the urgent clinical need in the field of ultra-long-acting postoperative pain relief and is an important achievement for the group in the central nervous system field.